Pulmonary function testing (PFT) is an indispensable tool in the diagnosis, monitoring, and management of respiratory diseases. However, interpretation of PFT results can be complex due to the multitude of factors influencing lung function. This article aims to provide a comprehensive guide to aid healthcare professionals in interpreting these results effectively.
Spirometry is the most common PFT, measuring the volume and speed of air a patient can inhale and exhale. The key parameters are Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC). A reduced FEV1/FVC ratio indicates obstructive lung disease, while a reduced FVC with a normal FEV1/FVC ratio suggests restrictive lung disease.
Diffusing capacity of the lungs for carbon monoxide (DLCO) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells. A decreased DLCO may indicate emphysema, pulmonary fibrosis, or pulmonary vascular disease.
Residual volume (RV), total lung capacity (TLC), and functional residual capacity (FRC) are important in diagnosing lung diseases. Increased RV and FRC suggest air trapping seen in obstructive diseases, while decreased TLC indicates restrictive diseases.
Assessing bronchodilator responsiveness helps differentiate between asthma and Chronic Obstructive Pulmonary Disease (COPD). An increase in FEV1 or FVC by 12% and 200ml after bronchodilator use is suggestive of asthma.
Interpreting PFTs is a complex task requiring understanding of various parameters and their implications. However, with a systematic approach, healthcare professionals can accurately diagnose and manage respiratory diseases. Continuous learning and experience are key to mastering this vital skill.
1.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
2.
Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?
3.
Chemo causes lasting physical decline in breast cancer survivors
4.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
5.
BMI is linked to heart damage from chemotherapy in breast cancer patients.
1.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
2.
Rehabilitation Following Bone Marrow Functional Suppression: Clinical Strategies and Advances
3.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
4.
Strategic Breakthroughs in Oncology in Clinical Decision-Making
5.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Early warning sings of camcer that need medical attention
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation